GlassScriptPhysician profile
Austin Chang
NPI 1710526983
$4,077.40
in general payments reported to CMS, 2019-2025
16 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $1,660 · 2023: $307 · 2024: $286 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Travel and Lodging: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.60 |
| Travel and Lodging | $945.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,576.01 | 2021-2023 | Intellis Adaptivestim |
| Atricure, INC. | $1,194.83 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System |
| Boston Scientific Corporation | $250.44 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Nalu Medical, INC. | $200.18 | 2022 | |
| Abbott Laboratories | $175.10 | 2025 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.06 | 2023-2025 | Relistor |
| Abbvie INC. | $114.77 | 2024 | |
| Spr Therapeutics, INC | $88.09 | 2025 | Sprint Pns System |
| Janssen Pharmaceuticals, INC | $77.74 | 2021-2022 | |
| Forte Bio-Pharma LLC | $76.13 | 2024 | Prolate, Nalocet |
| Pfizer INC. | $61.69 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $37.80 | 2023 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $29.12 | 2025 | |
| Merit Medical Systems INC | $28.76 | 2022 | |
| Tersera Therapeutics LLC | $18.52 | 2025 | Prialt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $13.16 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.